Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Despite advances in the management of epithelial ovarian cancer, it remains the most lethal of gynecological malignancies in the UK. Ovarian cancer is a complex disease, both in its molecular and clinical behavior. Targeted therapies have yet to show an improvement in five-year survival when added to standard cytotoxic chemotherapy. However, a recent redefinition of the disease along with the discovery of unique molecular targets has provided new avenues for therapeutic development. In this review, we summarize the main targeted therapies that are currently in clinical development alongside those that are due to enter the clinical arena.


Journal article


Cancer and Chemotherapy Reviews

Publication Date





37 - 44